14-day Premium Trial Subscription Sign Up For FreeGet Free

Alexion Pharmaceuticals Stock Forecast NASDAQ:ALXN

$182.50 (0%)

Volume: 0

Closed: Jan 26, 2022

Hollow Logo Score: 0.000

Alexion Pharmaceuticals Stock Forecast

$182.50 (0%)

Volume: 0

Closed: Jan 26, 2022

Score Hollow Logo 0.000

Alexion Pharmaceuticals Stock Price (Quote) NASDAQ:ALXN

$182.50 ( 0% ) Wednesday, 26th Jan 2022

Range Low Price High Price Comment
30 days $182.50 $182.50 Wednesday, 26th Jan 2022 ALXN stock ended at $182.50. During the day the stock fluctuated 0% from a day low at $182.50 to a day high of $182.50.
90 days $182.50 $182.50
52 weeks $146.97 $187.45

Historical Alexion Pharmaceuticals prices

Date Open High Low Close Volume
2022-01-26 $182.50 $182.50 $182.50 $182.50 0
2022-01-25 $182.50 $182.50 $182.50 $182.50 0
2022-01-24 $182.50 $182.50 $182.50 $182.50 0
2022-01-21 $182.50 $182.50 $182.50 $182.50 0
2022-01-20 $182.50 $182.50 $182.50 $182.50 0
2022-01-19 $182.50 $182.50 $182.50 $182.50 0
2022-01-18 $182.50 $182.50 $182.50 $182.50 0
2022-01-14 $182.50 $182.50 $182.50 $182.50 0
2022-01-13 $182.50 $182.50 $182.50 $182.50 0
2022-01-12 $182.50 $182.50 $182.50 $182.50 0
2022-01-11 $182.50 $182.50 $182.50 $182.50 0
2022-01-10 $182.50 $182.50 $182.50 $182.50 0
2022-01-07 $182.50 $182.50 $182.50 $182.50 0
2022-01-06 $182.50 $182.50 $182.50 $182.50 0
2022-01-05 $182.50 $182.50 $182.50 $182.50 0
2022-01-04 $182.50 $182.50 $182.50 $182.50 0
2022-01-03 $182.50 $182.50 $182.50 $182.50 0
2021-12-31 $182.50 $182.50 $182.50 $182.50 0
2021-12-30 $182.50 $182.50 $182.50 $182.50 0
2021-12-29 $182.50 $182.50 $182.50 $182.50 0
2021-12-28 $182.50 $182.50 $182.50 $182.50 0
2021-12-27 $182.50 $182.50 $182.50 $182.50 0
2021-12-23 $182.50 $182.50 $182.50 $182.50 0
2021-12-22 $182.50 $182.50 $182.50 $182.50 0
2021-12-21 $182.50 $182.50 $182.50 $182.50 0
2021-12-20 $182.50 $182.50 $182.50 $182.50 0
2021-12-17 $182.50 $182.50 $182.50 $182.50 0
2021-12-16 $182.50 $182.50 $182.50 $182.50 0
2021-12-15 $182.50 $182.50 $182.50 $182.50 0
2021-12-14 $182.50 $182.50 $182.50 $182.50 0
2021-12-13 $182.50 $182.50 $182.50 $182.50 0
2021-12-10 $182.50 $182.50 $182.50 $182.50 0
2021-12-09 $182.50 $182.50 $182.50 $182.50 0
2021-12-08 $182.50 $182.50 $182.50 $182.50 0
2021-12-07 $182.50 $182.50 $182.50 $182.50 0
2021-12-06 $182.50 $182.50 $182.50 $182.50 0
2021-12-03 $182.50 $182.50 $182.50 $182.50 0
2021-12-02 $182.50 $182.50 $182.50 $182.50 0
2021-12-01 $182.50 $182.50 $182.50 $182.50 0
2021-11-30 $182.50 $182.50 $182.50 $182.50 0
2021-11-29 $182.50 $182.50 $182.50 $182.50 0
2021-11-26 $182.50 $182.50 $182.50 $182.50 0
2021-11-24 $182.50 $182.50 $182.50 $182.50 0
2021-11-23 $182.50 $182.50 $182.50 $182.50 0
2021-11-22 $182.50 $182.50 $182.50 $182.50 0
2021-11-19 $182.50 $182.50 $182.50 $182.50 0
2021-11-18 $182.50 $182.50 $182.50 $182.50 0
2021-11-17 $182.50 $182.50 $182.50 $182.50 0
2021-11-16 $182.50 $182.50 $182.50 $182.50 0
2021-11-15 $182.50 $182.50 $182.50 $182.50 0

About Alexion Pharmaceuticals

Alexion Pharmaceuticals Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosp... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 108 000+ Happy Subscribers

Don't miss out on the runners!

Sign for StockInvest.us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT